Project Grant R21HD118554
- The National Institute of Child Health and Human Development awarded Duke University $694,448 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct research analyzing local and global responses in the placenta syncytiotrophoblast. The research investigates the multinucleated syncytiotrophoblast, a giant single cell that separates maternal and fetal vasculature during pregnancy and performs critical functions including nutrient...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $427,625 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and evaluate AI-guided self-scanning technology for prenatal ultrasound assessment. The project addresses limited access to obstetric ultrasound in underserved U.S. regions by piloting an integrated system combining low-cost point-of-care ultrasound...
- The National Institute of Child Health and Human Development awarded $668,485 to the University of California, San Diego on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate DNA repair mechanisms in hypoxia-induced placental genomic instability. The research examines increased genomic instability in placental villous tissue and trophoblast stem cells associated with maternal vascular malperfusion, a pattern of placental...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $108,421 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award funds research investigating the impact of state-level fetal protection laws on prenatal care, low birthweight, and preterm birth. The research applies controlled interrupted time series models to National Center for Health Statistics natality data to...
- The National Institute of Child Health and Human Development awarded Massachusetts General Hospital $499,918 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the genetic etiologies of stillbirth as an extreme manifestation within the developmental disorders continuum. The recipient will aggregate genomic and phenotypic data from an initial sequencing cohort of more than 1,000 stillbirth cases and their family members,...
- The National Institute of Child Health and Human Development awarded the University of North Carolina at Chapel Hill $1,172,712 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct a prospective cohort study examining the association between endometrial receptivity markers in menstrual effluent and fertility outcomes. The research will enroll 695 women from the community who are attempting to conceive and follow them for twelve...
- The National Institute of Child Health and Human Development awarded Harvard Pilgrim Health Care, Inc. $126,881 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and evaluate a decision support tool that facilitates informed, shared decision-making regarding prenatal cell-free DNA screening. The project, titled NIPT-AID: Navigating Prenatal Testing—Advancing Informed Decision-Making, addresses gaps between professional...
- The National Institute of Child Health and Human Development, part of the Department of Health and Human Services National Institutes of Health, awarded $456,500 to The University of Texas Southwestern Medical Center on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award funds molecular characterization of human pregnancy-induced cervical epithelium through two research aims. First, the recipient will apply single-cell and spatial...
- The National Institute of Child Health and Human Development (NICHD) of the Department of Health and Human Services awarded North Carolina State University $673,394 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to decode epigenetic networks that orchestrate endometrial function. The project addresses molecular mechanisms underlying uterine dysfunction in recurrent implantation failure and recurrent pregnancy loss, which remain major...
- The National Institute of Child Health and Human Development awarded the University of California, San Diego $230,388 on January 25, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the effects of rare damaging mutations in transforming growth factor-beta (TGFB) latent complex proteins found in preeclamptic placentas. The research examines how mutations in fibronectin 1 (FN1) and latent transforming growth factor beta binding protein 1...
The National Institute of Child Health and Human Development awarded $436,100 to the University of North Carolina at Charlotte on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and validate non-invasive high-resolution fetal HLA and KIR genotyping protocols using cell-free DNA from maternal blood. The project addresses preeclampsia risk stratification in early pregnancy by developing a high-resolution HLA genotyping protocol for cell-free fetal DNA and a corresponding bioinformatics pipeline to distinguish maternal and fetal genotypes from sequencing reads. The recipient will develop and validate a non-invasive method for fetal HLA genotyping from maternal blood cell-free DNA collected at 10–20 weeks of pregnancy using probe panel hybrid capture enrichment and sequencing on the Illumina platform, validated with maternal, paternal, and fetal samples. Additionally, the project will develop and validate a high-resolution fetal KIR genotyping protocol from maternal cell-free DNA, addressing structural variation and sequence homology challenges in the KIR region and validating results with maternal-fetal dyads and trios. Upon completion, the recipient expects to have a validated high-resolution fetal KIR-HLA genotyping protocol that facilitates development of a prognostic tool for preeclampsia. Performance occurs in Charlotte, NC 28223. The award covers the period of performance from September 1, 2026, through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/10/26 | ||
| Not listed | $436.1k | 8/6/26 |